Skip to main content
. Author manuscript; available in PMC: 2016 Nov 5.
Published in final edited form as: Cell. 2015 Nov 5;163(4):811–828. doi: 10.1016/j.cell.2015.10.044

Figure 4.

Figure 4

Therapeutic targeting of the Hippo pathway. (A) Potential roles of YAP/TAZ activity in tissue development and diseases. A confined window of YAP/TAZ activity is required for normal tissue development and homeostasis. (B) Strategies for targeting YAP/TAZ activity. Inhibitors for MST1/2, MAP4K4, and LATS1/2 can activate YAP/TAZ. YAP/TAZ-TEAD interaction may be disrupted by small molecules directly (Verteporfin) or AMPK activators (Metformin). Small molecules inhibiting Rho family GTPases or ROCK can indirectly activate LATS1/2, leading to YAP/TAZ inhibition.